Zymeworks Inc. business relationships
Companies named in Zymeworks Inc.’s 10-K filed 2026-03-02, and public companies whose annual reports name Zymeworks Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Zymeworks Inc.’s annual report 11
“2020 Research and License Agreement with Merck” SEC filing
“...earch period extension fee from collaboration partners Celgene Corporation and Celgene Alpine Investment Co. LLC (now a Bristol-Myers Squibb company, "BMS"), GlaxoSmithKline Intellectual Property Development Limited ("GSK"), Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo"), J&J, Merck Sharp & Dohme Resea...” SEC filing
“...), GlaxoSmithKline Intellectual Property Development Limited ("GSK"), Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo"), J&J, Merck Sharp & Dohme Research GmbH ("Merck"), primarily related to legacy platform collaboration agreements, as well as from BeOne related to our zanidatamab collaboration agreement...” SEC filing
“2016 Platform Technology Transfer and License Agreement with GSK” SEC filing
“At the conclusion of the research collaboration, both GSK and the Company will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate the Company's optimized immune-modulating Fc domains.” SEC filing
“...ale Agreement, Zymeworks BC sold to the Subsidiary a 30 % interest in future royalties from the license agreements with Jazz Pharmaceuticals Ireland Limited ("Jazz") and BeOne Medicines Ltd. ("BeOne") relating to Ziihera (zanidatamab‑hrii), not to exceed 120 % of the maximum amount payable (excludin...” SEC filing
“...18, 2022, the Zymeworks BC entered into a License and Collaboration Agreement (the "Jazz Collaboration Agreement") with Jazz Pharmaceuticals Ireland Limited ("Jazz"), under which Jazz will have development and commercialization rights of zanidatamab throughout the world, but excluding the People's R...” SEC filing
“...a 30 % interest in future royalties from the license agreements with Jazz Pharmaceuticals Ireland Limited ("Jazz") and BeOne Medicines Ltd. ("BeOne") relating to Ziihera (zanidatamab‑hrii), not to exceed 120 % of the maximum amount payable (excluding indemnification and other similar obligations) b...” SEC filing
“Termination and License Agreement by and between Zymeworks BC Inc. and Daiichi Sankyo Co., Ltd., effective as of February 28, 2023 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 8, 2023).” SEC filing
“2016 Collaboration Agreement with Daiichi Sankyo, Co., Ltd. ("Daiichi Sankyo")” SEC filing
“Research and License Agreement with LEO Pharma A/S ("LEO")” SEC filing
Companies whose annual reports name Zymeworks Inc. 4
“Our initial collaborator for the Zanidatamab Trial was Zymeworks Inc. (Zymeworks), however in a series of transactions commencing in October 2022, Jazz assumed responsibility from Zymeworks for the development and commercialization of zanidatamab in the United States, Europe, Japan and certain other...” SEC filing
“EU (licensed from Zymeworks) 3” SEC filing
“Within our oncology R&D program, in October 2022, we announced an exclusive licensing and collaboration agreement with Zymeworks providing us development and commercialization rights to Zymeworks' zanidatamab across all indications in the U.S., Europe, Japan and all other territories except for thos...” SEC filing
“Under our license and collaboration agreement with Zymeworks Inc. ("Zymeworks"), we have the right to develop and commercialize ZIIHERA ® in certain Asian pacific countries.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.